Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension

BMJ

Volumn 342, Issue 7802, 2011, Pages

  Ritter, J M ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENDROFLUMETHIAZIDE; BENZOTHIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ELECTROLYTE; LISINOPRIL; LOSARTAN; PLACEBO; RAMIPRIL; RENIN; TELMISARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN;

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; COUGHING; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DRUG COST; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME INHIBITION; ERECTILE DYSFUNCTION; FETUS DISEASE; GLOMERULUS FILTRATION RATE; HEALTH ECONOMICS; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; HYPOTENSION; IMPOTENCE; KIDNEY FAILURE; MICROALBUMINURIA; MORNING DOSAGE; OLIGOHYDRAMNIOS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SKULL DEFECT; SODIUM RESTRICTION; SURVIVAL; SYSTOLIC BLOOD PRESSURE; TERATOGENICITY; TREATMENT CONTRAINDICATION; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; URTICARIA; VASOCONSTRICTION;

ABNORMALITIES, DRUG-INDUCED; ACUTE KIDNEY INJURY; ANGIOEDEMA; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; COST-BENEFIT ANALYSIS; HUMANS; HYPERKALEMIA; HYPERTENSION; MEDICAL HISTORY TAKING; TREATMENT OUTCOME; URTICARIA;

EID: 79954575376     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d1673     Document Type: Article

References (27)

1. Dickerson JEC, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999;353:2008-13. (Pubitemid 29271745)
2. Brown MJ, Cruickshank JK, Dominiczak AF, MacGregor GA, Poulter NR, Russell GI, et al. Better blood pressure control: how to combine drugs. J Hum Hypertens 2003;17:81-6. (Pubitemid 36292361)
3. National Institute for Health and Clinical Excellence. Hypertension: management of hypertension in adults in primary care. (Clinical guideline 34.) 2006. http://guidance.nice.org.uk/CG34.
4. Ritter JM, Lewis LD, Mant TGK, Ferro A. Hypertension. In: A textbook of clinical pharmacology. 5th ed. Hodder Arnold, 2008:185-95.
5. Sciarretta S, Palano F, Tocci G, Baldini R, Volpe M. Antihypertensive treatment and development of heart failure in hypertension. Arch Intern Med 2010;8 Nov (Epub ahead of print). doi:10.1001/archinternmed.2010.427.
6. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
7. Okin PM, Deverenx RB, Harris KE, Jerne S, Kjeldsen SE, Julius S, et al. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalisation for for heart failure in hypertensive patients. Ann Intern Med 2007;147:311-9. (Pubitemid 351664558)
8. Flather MD, Yusuf S, Køber L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000;355:1575-8.
9. Salvetti A, Mattei P. Sudano I. Renal protection and antihypertensive drugs. Drugs 1999;57:665-93.
10. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in thecontext of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.
11. MacGregor GA, Markandu ND, Smith SJ, Sagnella GA. Captopril: contrasting effects of adding hydrochlorothiazide, propranolol or nifedipine. J Cardiovasc Pharmacol 1985;7(suppl 11):S82-7. (Pubitemid 15174508)
12. MacGregor GA, Markandu ND, Roulston JE, Jones JC, Morton JJ. Maintenance of blood pressure by the renin-angiotensin system in normal man. Nature 1981;291:329-31. (Pubitemid 11083433)
13. Menard J, Campbell DJ, Azizi M, Gonzales MF. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation 1997;96:3072-8. (Pubitemid 27500110)
14. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4.
15. Nakao NYA, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-24. (Pubitemid 36092015)
16. Nakao NYA, Morita H, Takada M, Kayano T, Ideura T., [Lancet editors. Retraction. Lancet 2009;374:1226.].
17. ONTARGET investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
18. Pfeffer MA, McMurray JJV, Velasquez EJ, Rouleau J-L, Kober L, Maggioni AP, et al. The valsartan in acute myocardial infarction trial I. Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventrcular dysfunction, or both. N Engl J Med 2003;349:1839-906.
19. Messerli FH. The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. JACC 2009;53:468-70.
20. McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 2006;332:1177-8.
21. National Heart Lung and Blood Institute. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. 2004. www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.htm.
22. Medical Research Party Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985;291:99-104.
23. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003. (Pubitemid 34286536)
24. Hermida RC, Ayala DE. Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing. Hypertension 2009;54:40-6.
25. Coleman JJ, McDowell SE, Evans Stephen JW, Gill, PS, Ferner RE. Oversight: a retrospective study of biochemical monitoring in patients beginning antihypertensive drug treatment in primary care. Br J Clin Pharmacol 2010;70:109-17.
26. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield MCe, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906. (Pubitemid 41265663)
27. Brown JJ, Davies DL, Lever AF, Robertson JIS. Plasma renin concentration in human hypertension. Relationship between renin, sodium and potassium. BMJ 1965;ii:144-8.